Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 75633, held by Sun Pharma Canada. Clobetasol Propionate.
As of Nov 16, 2026, ANDA 75633 (Clobetasol Propionate (Emollient)), held by Sun Pharma Canada, was first approved by FDA on May 17, 2000, with 3 approved supplements and 0 published complete response letters.
Clobetasol propionate cream, 0.05% (emollient) is a super-high potency corticosteroid indicated for: Clobetasol propionate cream, 0.05% (emollient) is a corticosteroid indicated for: The relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older. The treatment of moderate to severe plaque-type psoriasis in patients 16 years of age and older. Limitations of Use Clobetasol propionate cream, 0.05% (emollient) should not be used in the treatment of rosacea or perioral dermatitis, and should not be used on the face, groin, or axillae. The total dosage should not exceed 50 grams per week.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 17, 2000 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Clobetasol Propionate (Emollient)0.05% · cream;topical | Clobetasol Propionate | Rx |
| Nov 14, 2019 | Supplement 10Labeling · Standard review | Approved | None posted |
| Oct 2, 2001 | Supplement 2Manufacturing | Approved | None posted |
| Jan 24, 2001 | Supplement 1Manufacturing | Approved | None posted |
| May 17, 2000 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters